Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics

References

• Frey NA, Peng S, Cheng K, et al. Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and magnetic energy storage. Chem Soc Rev. 2009;38:2532–2542.
   PubMed Web of Science ®Google Scholar
• Jun Y, Choi J, Cheon J. Heterostructured magnetic nanoparticles: their versatility and high performance capabilities. Chem Comm. 2007;1203–1214.
   PubMed Web of Science ®Google Scholar
• Ambashta RD, Sillanpää M. Water purification using magnetic assistance: a review. J Hazard Mater. 2010;180:38–49.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Tan ALK, Tao Y, et al. Synthesis and characterization of iron oxide nanoparticles and applications in the removal of heavy metals from industrial wastewater. Int J Photoenergy. 2012;2012:1–5.
   Web of Science ®Google Scholar
• Wu W, Wu Z, Yu T, et al. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater. 2015;16:1–43.
   Web of Science ®Google Scholar
• Reimer P, Schuierer G, Balzer T, et al. Application of a superparamagnetic iron oxide (Resovist®) for MR imaging of human cerebral blood volume. Magn Reson Med. 1995;34:694–697.
   PubMed Web of Science ®Google Scholar
• Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266–1276.
   PubMed Web of Science ®Google Scholar
• Taboada E, Rodríguez E, Roig A, et al. Relaxometric and magnetic characterization of ultrasmall iron oxide nanoparticles with high magnetization. Evaluation as potential T1 magnetic resonance imaging contrast agents for molecular imaging. Langmuir. 2007;23:4583–4588.
   PubMed Web of Science ®Google Scholar
• Kim BH, Lee N, Kim H, et al. Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. J Am Chem Soc. 2011;133:12624–12631.
   PubMed Web of Science ®Google Scholar
• Wagner M, Wagner S, Schnorr J, et al. Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging. 2011;34:816–823.
   PubMed Web of Science ®Google Scholar
• Rui Y, Liang B, Hu F, et al. Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T1-weighted MRI. RSC Adv. 2016;6:22575–22585.
   Web of Science ®Google Scholar
• Vangijzegem T, Stanicki D, Boutry S, et al. VSION as high field MRI T1 contrast agent: evidence of their potential as positive contrast agent for magnetic resonance angiography. Nanotechnology. 2018;29:1–14.
   Web of Science ®Google Scholar
• Pham HN, Pham THG, Nguyen DT, et al. Magnetic inductive heating of organs of mouse models treated by copolymer coated Fe3O4 nanoparticles. Adv Nat Sci Nanosci Nanotechnol. 2017;8:1–10.
   Google Scholar
• Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995–4021.
   PubMed Web of Science ®Google Scholar
• Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8:147–166.
   PubMed Web of Science ®Google Scholar
• Karageorgis A, Dufort S, Sancey L, et al. An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors. Sci Rep. 2016;6:1–10.
   PubMed Web of Science ®Google Scholar
• Nichols JW, Bae YH. EPR: evidence and fallacy. J Control Release. 2014;190:451–464.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Holá K, Subr V, et al. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116:5338–5431.
   PubMed Web of Science ®Google Scholar
• Bietenbeck M, Florian A, Faber C, et al. Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now? Int J Nanomed. 2016;11:3191–3203.
   PubMed Web of Science ®Google Scholar
• Kumar JP, Prasad GK, Ramacharyulu PVRK, et al. Synthesis, characterization, and studies on decontamination of sulfur mustard. J Alloys Compd. 2017;692:833–840.
   Web of Science ®Google Scholar
• Sheng-Nan S, Chao W, Zan-Zan Z, et al. Magnetic iron oxide nanoparticles: synthesis and surface coating techniques for biomedical applications. Chin Phys B. 2014;23:1–19.
   Web of Science ®Google Scholar
• Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108:2064–2110.
   PubMed Web of Science ®Google Scholar
• Hola K, Markova Z, Zoppellaro G, et al. Tailored functionalization of iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of biosubstances. Biotechnol Adv. 2015;33:1162–1176.
   PubMed Web of Science ®Google Scholar
• Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug-delivery. Adv Drug Deliv Rev. 2011;63:789–808.
   PubMed Web of Science ®Google Scholar
• Teja AS, Koh P. Synthesis, properties, and applications of magnetic iron oxide nanoparticles. Prog Cryst Growth Charact Mater. 2009;55:22–45.
   Web of Science ®Google Scholar
• Fu C, Ravindra NM. Magnetic iron oxide nanoparticles: synthesis and applications. Bioinspir Biomim Nan. 2012;1:229–244.
   Web of Science ®Google Scholar
• Qiao R, Yang C, Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mat Chem. 2009;19:6274–6293.
   Google Scholar
• Pereira C, Pereira AM, Fernandes C, et al. Superparamagnetic MFe2O4 (M = Fe, Co, Mn) nanoparticles: tuning the particle size and magnetic properties through a novel one-step coprecipitation route. Chem Mater. 2012;24:1496–1504.
   Web of Science ®Google Scholar
• Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 1981;17:1247–1248.
   Web of Science ®Google Scholar
• Belaïd S, Laurent S, Vermeersch M, et al. A new approach to follow the formation of iron oxide nanoparticles synthesized by thermal decomposition. Nanotechnology. 2013;24:1–9.
   Web of Science ®Google Scholar
• Belaïd S, Stanicki D, Vander Elst L, et al. Influence of experimental parameters on iron oxide nanoparticles properties synthesized by thermal decomposition: size and nuclear magnetic resonance studies. Nanotechnology. 2018;29:1–12.
   Web of Science ®Google Scholar
• Stanicki D, Boutry S, Laurent S, et al. Carboxy-silane coated iron oxide nanoparticles: a convenient platform for cellular and small animal imaging. J Mat Chem B. 2014;2:387–397.
   Web of Science ®Google Scholar
• Laurent S, Saei AA, Behzadi S, et al. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv. 2014;11:1449–1470.
   PubMed Web of Science ®Google Scholar
• Mallakpour S, Madani M. A review of current coupling agents for modification of metal oxide nanoparticles. Prog Org Coat. 2015;86:194–207.
   Web of Science ®Google Scholar
• Mahmoudi M, Sant S, Wang B, et al. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63:24–46.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Naregalkar RR, Vaidya VD, et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine. 2007;2:23–39.
   PubMed Web of Science ®Google Scholar
• Thanh NTK. Clinical applications of magnetic nanoparticles. Boca Raton: CRC Press; 2018.
   Google Scholar
• Ling D, Lee N, Hyeon T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc Chem Res. 2015;48:1276–1285.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
   PubMed Web of Science ®Google Scholar
• Estanqueiro M, Amaral MH, Conceição J, et al. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631–648.
   PubMed Web of Science ®Google Scholar
• Cole AJ, Yang VC, David AE. Cancer theranostics: the rise of targeted nanoparticles. Trends Biotechnol. 2011;29:323–332.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440–446.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:1–11.
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower PH, Wiernik PH. Hypersensitivity reactions from taxol. J Clin Oncol. 2014;8:1263–1268.
   Google Scholar
• Kampan N, Madondo M, McNally O, et al. Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Res Int. 2015;2015:1–21.
   Web of Science ®Google Scholar
• Konstat-Korzenny E, Ascencio-Aragón J, Niezen-Lugo S, et al. Artemisinin and its synthetic derivatives as a possible therapy for cancer. Med Sci. 2018;6:1–10.
   Google Scholar
• Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012;2012:1–18.
   PubMedGoogle Scholar
• Cavalcante LS, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16.
   PubMed Web of Science ®Google Scholar
• Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239–253.
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, et al. Velcade®:U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–513.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2015;5:364–378.
   Google Scholar
• Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407–415.
   PubMed Web of Science ®Google Scholar
• Xie J, Chen K, Huang J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31:3016–3022.
   PubMed Web of Science ®Google Scholar
• Quan Q, Xie J, Gao H, et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol Pharm. 2011;8:1669–1676.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang J, Niu G. Human serum albumin coated iron oxide nanoparticles for efficient cell labelling. Chem Comm. 2010;46:433–435.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®- The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Huang Y, Mao K, Zhang B, et al. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics. Mat Sci Eng C. 2017;70:763–771.
   PubMed Web of Science ®Google Scholar
• Yang Y, Guo Q, Peng J, et al. Doxorubicin-conjugated heparin-coated superparamagnetic iron oxide nanoparticles for combined anticancer drug delivery and magnetic resonance imaging. J Biomed Nanotech. 2016;12:1963–1974.
   PubMed Web of Science ®Google Scholar
• Estelrich J, Escribano E, Queralt J, et al. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci. 2015;16:8070–8101.
   PubMed Web of Science ®Google Scholar
• Issa B, Obaidat IM, Albiss BA, et al. Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int J Mol Sci. 2013;14:21266–21305.
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Brown SD, Holden MR, et al. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg Chim Acta. 2012;393:328–333.
   Web of Science ®Google Scholar
• Lyon JL, Fleming DA, Stone MB, et al. Synthesis of Fe oxide core/Au shell nanoparticles by iterative hydroxylamine seeding. Nano Lett. 2004;4:719–723.
   Web of Science ®Google Scholar
• Brown SD, Nativo P, Smith J, et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010;132:4678–4684.
   PubMed Web of Science ®Google Scholar
• Craig GE, Brown SD, Lamprou DA, et al. Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval? Inorg Chem. 2012;51:3490–3497.
   PubMed Web of Science ®Google Scholar
• Unterweger H, Tietze R, Janko C, et al. Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery. Int J Nanomedicine. 2014;9:3659–3676.
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23:605–618.
   PubMed Web of Science ®Google Scholar
• Jeong Y, Kim S, Jin S, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. Pharm Nanotechnol. 2008;97:1268–1276.
   Google Scholar
• Sugahara KN, Hirata T, Hayasaka H, et al. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861–5868.
   PubMed Web of Science ®Google Scholar
• Nadeem M, Ahmad M, Akhtar MS, et al. Magnetic properties of polyvinyl alcohol and doxorubicine loaded iron oxide nanoparticles for anticancer drug delivery applications. PLoS ONE. 2016;11:1–12.
   Web of Science ®Google Scholar
• Zaloga J, Janko C, Nowak J. Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility. Int J Nanomed. 2014;9:4847–4866.
   PubMed Web of Science ®Google Scholar
• Zaloga J, Pöttler M, Leitinger G, et al. Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting. Eur J Pharm Biopharm. 2016;101:152–162.
   PubMed Web of Science ®Google Scholar
• Natesan S, Ponnusamy C, Sugumaran A, et al. Artemisinin loaded chitosan magnetic nanoparticles for the efficient targeting to the breast cancer. Int J Biol Macromol. 2017;104:1853–1859.
   PubMed Web of Science ®Google Scholar
• Rodrigues S, Dionísio M, López CR, et al. Biocompatibility of chitosan carriers with application in drug delivery. J Funct Biomater. 2012;3:615–641.
   PubMedGoogle Scholar
• Thapa D, Palkar VR, Kurup MB, et al. Properties of magnetite nanoparticles synthesized through a novel chemical route. Matt Lett. 2004;58:2692–2694.
   Web of Science ®Google Scholar
• Calvo P, Remuñán-López C, Vila-Jato JL, et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63:125–132.
   Web of Science ®Google Scholar
• Jeon H, Kim J, Lee YM, et al. Poly-paclitaxel/cyclodextrin-SPION nano-assembly for magnetically guided drug delivery system. J Control Release. 2016;231:68–76.
   PubMed Web of Science ®Google Scholar
• Du X, Khan AR, Fu M, et al. Current development in the formulations of non-injection administration of paclitaxel. Int J Pharm. 2018;542:242–252.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62:284–304.
   PubMed Web of Science ®Google Scholar
• Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7:2078–2089.
   PubMed Web of Science ®Google Scholar
• Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388–395.
   PubMed Web of Science ®Google Scholar
• Mu Q, Kievit FM, Kant RJ, et al. Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. Nanoscale. 2015;7:18010–18014.
   PubMed Web of Science ®Google Scholar
• Ahmed MSU, Salam AB, Yates C, et al. Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Int J Nanomed. 2017;12:6973–6984.
   PubMed Web of Science ®Google Scholar
• Nagesh PKB, Johnson NR, Boya VKN, et al. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B. 2016;144:8–20.
   PubMed Web of Science ®Google Scholar
• Leach JC, Wang A, Ye K, et al. A RNA-DNA hybrid aptamer for nanoparticle-based prostate tumor targeted drug delivery. Int J Mol Sci. 2016;17:1–11.
   Web of Science ®Google Scholar
• Aires A, Ocampo SM, Simões BM. Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology. 2016;27:1–10.
   Web of Science ®Google Scholar
• Latorre A, Couleaud P, Aires A, et al. Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach. Eur J Med Chem. 2014;82:355–362.
   PubMed Web of Science ®Google Scholar
• Trabulo S, Aires A, Aicher A, et al. Multifunctionalized iron oxide nanoparticle for selective targeting of pancreatic cancer cells. Biochim Biophys Acta. 2017;1861:1597–1605.
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991–1003.
   PubMed Web of Science ®Google Scholar
• Karimi M, Eslami M, Sahandi-Zangabad P. pH-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. WIREs Nanomed Nanobiotechnol. 2016;8:696–716.
   PubMed Web of Science ®Google Scholar
• Kievit FM, Wang FY, Fang C, et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release. 2011;152:76–83.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–234.
   PubMed Web of Science ®Google Scholar
• Fang C, Bhattarai N, Sun C, et al. Functionalized nanoparticles with long-term stability in biological media. Small. 2009;5:1637–1641.
   PubMed Web of Science ®Google Scholar
• Gautier J, Munnier E, Paillard A, et al. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. Int J Pharm. 2012;423:16–25.
   PubMed Web of Science ®Google Scholar
• Hervé K, Douziech-Eyrolles L, Munnier E, et al. The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications. Nanotechnology. 2008;19:1–7.
   PubMed Web of Science ®Google Scholar
• Munnier E, Cohen-Jonathan S, Linassier C, et al. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. Pharm Nanotechnol. 2008;363:170–176.
   Google Scholar
• Wimardhani YS, Suniarti DF, Freisleben HJ, et al. Chitosan exerts anticancer activity through induction of apoptosis and cell cycle arrest in oral cancer cells. J Oral Sci. 2014;56:119–126.
   PubMed Web of Science ®Google Scholar
• Dash M, Chiellini F, Ottenbrite RM, et al. Chitosan – A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci. 2011;36:981–1014.
   Web of Science ®Google Scholar
• Unsoy G, Yalcin S, Khodadust R, et al. Chitosan magnetic nanoparticles for pH responsive bortezomib release in cancer therapy. Biomed Pharmacother. 2014;68:641–648.
   PubMed Web of Science ®Google Scholar
• Unsoy G, Yalcin S, Khodadust R, et al. Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications. J Nanopart Res. 2012;14:1–13.
   PubMed Web of Science ®Google Scholar
• Unsoy G, Khodadust R, Yalcin S, et al. Synthesis of doxorubicin loaded magnetic chitosan nanoparticles for pH responsive targeted drug delivery. Eur J Pharm Sci. 2014;62:243–250.
   PubMed Web of Science ®Google Scholar
• Adimoolam MG, Amreddy N, Nalam MR, et al. A simple approach to design chitosan functionalized Fe3O4 nanoparticles for pH responsive delivery of doxorubicin for cancer therapy. J Magn Magn Mater. 2018;448:199–207.
   Web of Science ®Google Scholar
• Zou Y, Liu P, Liu C, et al. Doxorubicin-loaded mesoporous magnetic nanoparticles to induce apoptosis in breast cancer cells. Biomed Pharmacother. 2015;69:355–360.
   PubMed Web of Science ®Google Scholar
• Quinto CA, Mohindra P, Tong S, et al. Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. Nanoscale. 2015;7:12728–12736.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Lee B. Protein corona: a new approach for nanomedicine design. Int J Nanomed. 2017;12:3137–3151.
   PubMed Web of Science ®Google Scholar
• Pederzoli F, Tosi G, Vandelli MA, et al. Protein corona and nanoparticles: how can we investigate on? WIREs Nanomed Nanobiotechnol. 2017;9:1–23.
   Web of Science ®Google Scholar